Diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes: diagnosis and treatment
- 作者: Mangasarova Y.K1, Magomedova AU1, Kravchenko SK1, Zvonkov EE1, Kremenetskaya AM1, Vorobyev VI1, Maryin DS1, Gubkin AV1, Skidan NI1, Kaplanskaya IB1, Vorobyev IA1, Samoilova RS1, Vorobyev AI1
-
隶属关系:
- Hematology Research Center, Russian Academy of Medical Sciences
- 期: 卷 82, 编号 7 (2010)
- 页面: 61-65
- 栏目: Editorial
- ##submission.dateSubmitted##: 09.04.2020
- ##submission.datePublished##: 15.07.2010
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30640
- ID: 30640
如何引用文章
全文:
详细
Subjects and methods. The study included 15 patients (6 men and 9 women aged 18 to 70 years; median 38 years) followed up at the Hematology Research Center, Russian Academy of Medical Sciences, in 2004 to 2009. Three and 12 patients had Stages II and IIE DLBCLS, respectively. B symptoms were found in 14 (93.4%) patients. Increased lactate dehydrogenase (LDH) concentrations were detectable in 14 (93.4%) patients; tumors of 10 cm or more (bulky disease) were seen in 11 (73.3%). Enlarged cervical, supraclavicular, and axillary lymph nodes were found in 9 (60%) patients; lung involvement via extension in 9 (60%), and invasion into the pericardium in 5 (33.3%) and soft tissues of the anterior thoracic wall in (13.3%). There were no signs of involvement of extranodal organs at the moment of diagnosis. All the 15 patients received PCT according to the modified NHL-BFM-90 program: 4 to 6 courses depending on the response to the therapy; 10 (66.6%) and 5 (33.3%) patients had 4 and 6 courses, respectively; for consolidating purpose, 11 (78.5%) patients were prescribed radiotherapy applied to the mediastinum in a cumulative dose of 36 Gy due to the fact that they had a residual mass.
Results. Thirteen (86.6%) patients achieved a complete remission (CR). Primary PCT resistance was confirmed in one case. Another patient was stated to have near-complete remission. No recurrences were notified during the follow-up. The mean CR duration was 24.5 (range 2-49) months.
Conclusion. DLBCLS with primary LN involvement is an individual nosological entity to be differentiated from primary mediastinal large B-cell lymphosarcoma. In most cases, DLBCLS shows signs of a poor prognosis, which makes it necessary to perform aggressive PCT.
作者简介
Ya Mangasarova
Hematology Research Center, Russian Academy of Medical Sciences
Email: v.k.jana@mail.ru
Hematology Research Center, Russian Academy of Medical Sciences
A Magomedova
Hematology Research Center, Russian Academy of Medical Sciences
Email: maminat@mail.ru
Hematology Research Center, Russian Academy of Medical Sciences
S Kravchenko
Hematology Research Center, Russian Academy of Medical Sciences
Email: krav@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences
E Zvonkov
Hematology Research Center, Russian Academy of Medical Sciences
Email: zvonkov@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences
A Kremenetskaya
Hematology Research Center, Russian Academy of Medical Sciences
Email: mtkalexandra@gmail.com
Hematology Research Center, Russian Academy of Medical Sciences
V Vorobyev
Hematology Research Center, Russian Academy of Medical Sciences
Email: morela@mail.ru
Hematology Research Center, Russian Academy of Medical Sciences
D Maryin
Hematology Research Center, Russian Academy of Medical Sciences
Email: dmdoc@mail.ru
Hematology Research Center, Russian Academy of Medical Sciences
A Gubkin
Hematology Research Center, Russian Academy of Medical Sciences
Email: gubkin@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences
N Skidan
Hematology Research Center, Russian Academy of Medical Sciences
Email: nskidan@rabmler.ru
Hematology Research Center, Russian Academy of Medical Sciences
I Kaplanskaya
Hematology Research Center, Russian Academy of Medical Sciences
Email: irinak@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences
I Vorobyev
Hematology Research Center, Russian Academy of Medical Sciences
Email: ivorobjev@mail.ru
Hematology Research Center, Russian Academy of Medical Sciences
R Samoilova
Hematology Research Center, Russian Academy of Medical Sciences
Email: tb@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences
A Vorobyev
Hematology Research Center, Russian Academy of Medical Sciences
Email: director@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences
参考
- Swerdlow S. H., Campo E. et al. Diffuse large B-cell lymphoma, not otherwise specified. In: WHO classification of hematopoetic and lymphoid tissues. Lyon; 2008. 233-237.
- Isaacson P. G., Norton A., Addis B. The human thymus contains a novel population of B-lymphocytes. Lancet 1987; 2: 1488-1491.
- Bertran H. C., Check I. J., Milano M. A. Immunophenotyping large B-cell lymphomas flow cytometric pitfalls and pathologic correlation. Am. J. Clin. Pathol. 2001; 116: 191-203.
- Loddeenkemper C., Anagnostopoulos I., Hummel M. et al. Differential Emu enhancer activity expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J. Pathol. 2004: 202; 60-69.
- Winter J. N., Weller E. A., Horning S. J. et al. Prognostic significance of bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: prospective correlative study. Blood. 2006; 107 (11): 4207-4213.
- Barrans S., Evans P., Connor S. et al. The t(14;18) is associated with germinal center-derived diffuse B-cell lymphoma and is a strong predictor. Clin. Cancer Res. 2003; 9: 2133-2139.
- Ковригина А. М., Пробатова Н. А. Лимфома Ходжкина и крупноклеточные лимфомы. М.: МИА; 2007. 108-124.
- Leithauser F., Bauerle M., Huynh M. Q. et al. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lasc of ongoing mutation activity are prelevant in mediastinal B-cell lymphoma. Blood 2001; 98: 2762-2770.
- Copie- Bergman C., Gaulard P., Maouche-Chrétien L. et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood 1999; 94: 3567-3575.
- Barans S., Connor S., Evans P. et al. Rearrangement of the BCL-6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br. J. Haematol. 2002; 117: 322-332.
- Магомедова А. У. Диффузная В-крупноклеточная лимфосаркома лимфоидных органов: клинические формы, лечение. Автореф. дис. ... д-ра мед. наук. М.; 2008.
- Bentz M., Barth T., Bruderlein S. et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): Comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes, Chromos. Cancer 2001; 30: 393-401.
- Feugier P., Van Hoof A., Sebban S. et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse Large B-cell lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 2005; 23: 4117-4126.
- Поддубная В. И., Османов Д. Ш., Бабичева Л. Г. и др. Сравнительная характеристика эффективности схем СНОР и Мабтера + СНОР (R-CHOP) в лечении больных диффузной крупноклеточной В-клеточной неходжкинской лимфомой. Соврем. онкол. 2004; 6: 39-41.
- Звонков Е. Е., Кременецкая А. М., Кравченко С. К. и др. Эффективность консервативной терапии лимфосаркомы желудка. Тер. арх. 2008; 7: 18-26.
- Магомедова А. У., Кравченко С. К., Кременецкая А. М. и др. Модифицированная программа NHL-BFM-90 в лечении больных диффузной В-крупноклеточной лимфосаркомой. Тер. арх. 2006; 10: 44-47.
- Барях Е. А., Звонков Е. Е., Кременецкая А. М. и др. Лечение беркиттоподобной лимфомы взрослых. Тер. арх. 2005; 8: 53-57.
- Магомедова А. У., Кравченко С. К., Кременецкая А. М. Диффузная В-крупноклеточная лимфосаркома. Диагностические критерии, алгоритм обследования и основные программы лечения. Пробл. гематол. 2004; 2: 26-28.
- Zinzani P. L., Martelli M., Bertini M. et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002; 87: 1258- 1264.
- Cheson B. D., Pfistner B., Juweid M. E. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 2007; 25 (5): 579-586.
补充文件
![](/img/style/loading.gif)